ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/DNA-methyltransferase
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/DNA-methyltransferase
20
trial(s) found.
NCT06508489
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies (
TCD17796
)
NKp46-based NK-cell engager
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06456463
Haem
Phase 2
Recruiting
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (
TRILLIUM
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
IL-3 diphtheria toxin fusion protein
antimetabolite
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06372717
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Hollywood Private Hospital
NCT05756322
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (
LBS-007-CT01
)
CDC7 inhibitor
+ DNA methyltransferase inhibitor
Leukaemia
NSW
2500 - Wollongong - Wollongong Private Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT05636514
Haem
Phase 1
Recruiting
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia (
CELESTIAL-MDS
)
DNA methyltransferase inhibitor
FAK inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
NCT05453903
Paed
Phase 1
Recruiting
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (
CR109124
)
KMT2A inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
Bcl2 inhibitor
anti-CD33 antibody-drug conjugate
antimetabolite
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04964518
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03850574
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (
TUSCANY
)
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
+ DNA methyltransferase inhibitor
Chronic myelomonocytic leukaemia
Leukaemia
Myelodysplastic syndrome
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4812 - Townsville - Townsville University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12625000201471
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG MDS05 (MYDAS-T)/D3 (MESSAGE): Myelodysplasia Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement (
MDS05-D3
)
Cedazuridine
DNA methyltransferase inhibitor
Decitabine
cancer therapy
cancer therapy,DNA methyltransferase-targeting
cancer therapy,cytidine deaminase-targeting
cytidine deaminase inhibitor
+ DNA methyltransferase inhibitor
Solid tumour
ACTRN12624000738527
Haem
Phase 2
Not yet recruiting
AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy. (
AMLM22-D4-CADENCE
)
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12624000065594
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
ACTRN12623000900617
Haem
Not Applicable
Not yet recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12621001713886
Haem
Phase 1 / Phase 2
Recruiting
MDS05/D1: (MYDAS-T) Assessing the safety of ES-3000 and ASTX727 in patients with myelodysplasia (
MYDAS-T-Run-ES-IN
)
cytidine deaminase inhibitor
+ DNA methyltransferase inhibitor
Solid tumour
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 42 in
/home/topowadl/articanz.org/table.php
on line
430
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M-(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not yet recruiting (5)
Recruitment Country and State
VIC (13)
NSW (11)
WA (9)
QLD (8)
SA (4)
NZ (3)
NT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (10)
Phase 2 (3)
Phase 3 (2)
Phase 4 (1)
Trial Type
Haem (18)
Paed (2)
Cancer Therapy Class
DNA methyltransferase
100%
Bcl2
50%
cytidine deaminase
20%
IDH1
5%
IDH1 R132
5%
ISR
5%
multikinase
5%
CDC7
5%
FAK
5%
KMT2A
5%
CD33
5%
BRD4
5%
TIM3
5%
GM-CSF
5%
Facility
3168 - Clayton - Monash Medical Centre (7)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
6000 - Perth - Royal Perth Hospital (4)
3004 - Melbourne, Southbank - Alfred Health (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2139 - Concord - Concord Repatriation General Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2500 - Wollongong - Wollongong Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3066 - Epping - Northern Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
6009 - Nedlands - Hollywood Private Hospital (2)
4217 - Benowa - Pindara Private Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2217 - Kogarah - St George Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4215 - Southport - Gold Coast University Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
6009 - Nedlands - One Clinical Research (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4812 - Townsville - Townsville University Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Myeloproliferative neoplasm
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Chronic myelomonocytic leukaemia
Solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy